Sarepta Therapeutics (SRPT) Misses Q2 EPS by 7c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall St set for higher open tech gains offset bond-market jitters
- Oil prices rise as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Alphabet shares up in premarket trade after Gemini 4 Argon launch
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
August 2, 2022 4:06 PM EDT-Â Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2022 totaled $233.5 million
-Â Net product revenues for the second quarter 2022 totaled $211.2 million, a 49% increase over the same quarter of prior year
-Â Â Increased full-year total revenue and net product revenue guidance to a range of $905-$920 million and $825-$840 million, respectivelyÂ
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the... More
